Bessemer Group
MLTX icon

Bessemer Group’s MoonLake Immunotherapeutics MLTX Stock Holding History

Bessemer Group’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-710
Closed -$8.38K – 2644
2025
Q3 		$6K Buy
710
+610
+610% +$31.8K ﹤0.01% 2100
2025
Q2 		$5K Buy
+100
New +$4.07K ﹤0.01% 2031

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Bessemer Group's MLTX Position: Q4 2025 in Review

Bessemer Group sold out of MoonLake Immunotherapeutics (MLTX) in Q4 2025, closing a stake of 710 shares — an estimated $8.38K sold.

Bessemer Group first reported a position in MLTX in Q2 2025 and held it in 2 quarters. The position peaked at $6K in Q3 2025. 130 funds tracked by Wall St. Rank hold MLTX as of Q4 2025.

  • Bessemer Group reported no remaining MoonLake Immunotherapeutics position as of Q4 2025 after selling out during the quarter.
  • Bessemer Group sold 710 MoonLake Immunotherapeutics shares in Q4 2025, an estimated $8.38K.
  • Bessemer Group first reported a position in MoonLake Immunotherapeutics in Q2 2025 and held it in 2 quarters.
  • Bessemer Group's MoonLake Immunotherapeutics position peaked at $6K in Q3 2025.
  • 130 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q4 2025.

Based on Bessemer Group's 13F filing for Q4 2025, filed 5 Feb 2026.